VYNE Therapeutics Inc.VYNENASDAQ
Loading
EV to Sales: Discounted ValuationCompressed
Percentile Rank30
5Y CAGR-30.8%
Year-over-Year Change
Enterprise value to sales ratio
5Y CAGR
-30.8%/yr
Long-term compound
Percentile
P30
Within normal range
vs 5Y Ago
0.2x
Contraction
Streak
1 yr
Consecutive declineCompressed
| Period | Value | YoY Change |
|---|---|---|
| 2025 | 1.37 | -99.4% |
| 2024 | 245.20 | +1706.9% |
| 2023 | -15.26 | +67.4% |
| 2022 | -46.76 | -511.1% |
| 2021 | 11.37 | +31.1% |
| 2020 | 8.67 | -97.0% |
| 2019 | 287.59 | +7595.2% |
| 2018 | 3.74 | -97.1% |
| 2017 | 126.82 | -86.2% |
| 2016 | 922.05 | - |